Patents by Inventor Dingjiang Liu
Dingjiang Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230415073Abstract: The present disclosure relates to, inter alia, a method of quantitating an amount of an antibody molecule from a mixture comprising two or more antibody molecules, comprising separating each of the two or more antibody molecules from the mixture by hydrophobic interaction chromatography high performance liquid chromatography (HIC-HPLC) and quantitating an amount of each antibody molecule, wherein the molecular weight of each antibody molecule is within 15 kDa of any other antibody molecule in the mixture and either each antibody molecule is different from another antibody molecule in the mixture by more than about 0.25 unit on the Kyte & Doolittle hydropathy scale or each of the antibody molecules when nm alone on HIC-HPLC elutes at distinct run time with little overlap from the other antibody molecules in the mixture, or both.Type: ApplicationFiled: August 30, 2023Publication date: December 28, 2023Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Dingjiang LIU, Lin LUO, Long XU
-
Patent number: 11850535Abstract: The present disclosure relates to, inter alia, a method of quantitating an amount of an antibody molecule from a mixture comprising two or more antibody molecules, comprising separating each of the two or more antibody molecules from the mixture by hydrophobic interaction chromatography high performance liquid chromatography (HIC-HPLC) and quantitating an amount of each antibody molecule, wherein the molecular weight of each antibody molecule is within 15 kDa of any other antibody molecule in the mixture and either each antibody molecule is different from another antibody molecule in the mixture by more than about 0.25 unit on the Kyte & Doolittle hydropathy scale or each of the antibody molecules when nm alone on HIC-HPLC elutes at distinct run time with little overlap from the other antibody molecules in the mixture, or both.Type: GrantFiled: December 19, 2022Date of Patent: December 26, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Dingjiang Liu, Lin Luo, Long Xu
-
Publication number: 20230293724Abstract: The present disclosure provides stable lyophilized pharmaceutical compositions comprising recombinant adeno-associated virus (rAAV) particles. In certain embodiments, the compositions contain, in addition to the rAAV particles, a buffer, one or more salts, a surfactant, a bulking agent, and a sugar. The pharmaceutical compositions of the present disclosure exhibit a substantial degree of rAAV stability upon stress and storage.Type: ApplicationFiled: March 13, 2023Publication date: September 21, 2023Inventors: Dingjiang Liu, Li Zhi, Yao Chen, Kuan-Yu Lai, Jonathan Wert, Xiaoyan Wang
-
Publication number: 20230192873Abstract: The present disclosure relates to AM-14 pharmaceutical formulations and therapeutic dosing regimens for the treatment of disease.Type: ApplicationFiled: October 11, 2022Publication date: June 22, 2023Inventors: Dingjiang Liu, Holly Zhuohong Huang, David Andrew Martin, Christopher Boyd Russell, David H. Salinger, Scott Walter Baumgartner, Christopher Endres
-
Publication number: 20230183348Abstract: The present invention provides stable pharmaceutical formulations comprising a human antibody that specifically binds to human programmed death-1 protein (PD-1). In certain embodiments, the formulations contain, in addition to an anti-PD-1 antibody, a buffer, an amino acid, a non-ionic surfactant, and a sugar. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability upon stress and storage.Type: ApplicationFiled: February 1, 2023Publication date: June 15, 2023Inventors: Qingyan Hu, Dingjiang Liu
-
Publication number: 20230119592Abstract: The present disclosure relates to, inter alia, a method of quantitating an amount of an antibody molecule from a mixture comprising two or more antibody molecules, comprising separating each of the two or more antibody molecules from the mixture by hydrophobic interaction chromatography high performance liquid chromatography (HIC-HPLC) and quantitating an amount of each antibody molecule, wherein the molecular weight of each antibody molecule is within 15 kDa of any other antibody molecule in the mixture and either each antibody molecule is different from another antibody molecule in the mixture by more than about 0.25 unit on the Kyte & Doolittle hydropathy scale or each of the antibody molecules when run alone on HIC-HPLC elutes at distinct run time with little overlap from the other antibody molecules in the mixture, or both.Type: ApplicationFiled: December 19, 2022Publication date: April 20, 2023Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Dingjiang LIU, Lin LUO, Long XU
-
Patent number: 11603407Abstract: The present invention provides stable pharmaceutical formulations comprising a human antibody that specifically binds to human programmed death-1 protein (PD-1). In certain embodiments, the formulations contain, in addition to an anti-PD-1 antibody, a buffer, an amino acid, a non-ionic surfactant, and a sugar. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability upon stress and storage.Type: GrantFiled: March 21, 2018Date of Patent: March 14, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Qingyan Hu, Dingjiang Liu
-
Patent number: 11596690Abstract: The present invention provides pharmaceutical formulations comprising an antibody that specifically binds to human interleukin-33 (hIL-33). The formulations may contain, in addition to an anti-IL-33 antibody, a buffer, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months and after being subjected to thermal and other physical stresses.Type: GrantFiled: March 20, 2020Date of Patent: March 7, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Qingyan Hu, Dingjiang Liu
-
Patent number: 11571636Abstract: The present disclosure relates to, inter alia, a method of quantitating an amount of an antibody molecule from a mixture comprising two or more antibody molecules, comprising separating each of the two or more antibody molecules from the mixture by hydrophobic interaction chromatography high performance liquid chromatography (HIC-HPLC) and quantitating an amount of each antibody molecule, wherein the molecular weight of each antibody molecule is within 15 kDa of any other antibody molecule in the mixture and either each antibody molecule is different from another antibody molecule in the mixture by more than about 0.25 unit on the Kyte & Doolittle hydropathy scale or each of the antibody molecules when nm alone on HIC-HPLC elutes at distinct run time with little overlap from the other antibody molecules in the mixture, or both.Type: GrantFiled: May 17, 2021Date of Patent: February 7, 2023Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Dingjiang Liu, Lin Luo, Long Xu
-
Publication number: 20230020428Abstract: Methods for determining the relative abundance of intact adeno-associated virus (AAV) capsid components in a sample of recombinant AAV particles are disclosed. In embodiments, the methods include a system regeneration process that minimizes or eliminates the presence of ghost peaks to maximize analytical accuracy and ensure product quality and consistency.Type: ApplicationFiled: July 11, 2022Publication date: January 19, 2023Inventors: Jonathan Wert, Li Zhi, Dingjiang Liu
-
Patent number: 11505612Abstract: The present disclosure relates to AM-14 pharmaceutical formulations and therapeutic dosing regimens for the treatment of disease.Type: GrantFiled: September 8, 2020Date of Patent: November 22, 2022Assignee: AMGEN K-A, INC.Inventors: Dingjiang Liu, Holly Zhuohong Huang, David Andrew Martin, Christopher Boyd Russell, David H. Salinger, Scott Walter Baumgartner, Christopher Endres
-
Patent number: 11369896Abstract: The present disclosure relates to, inter alia, a method of quantitating an amount of an antibody molecule from a mixture comprising two or more antibody molecules, comprising separating each of the two or more antibody molecules from the mixture by hydrophobic interaction chromatography high performance liquid chromatography (HIC-HPLC) and quantitating an amount of each antibody molecule, wherein the molecular weight of each antibody molecule is within 15 kDa of any other antibody molecule in the mixture and either each antibody molecule is different from another antibody molecule in the mixture by more than about 0.25 unit on the Kyte & Doolittle hydropathy scale or each of the antibody molecules when run alone on HIC-HPLC elutes at distinct run time with little overlap from the other antibody molecules in the mixture, or both.Type: GrantFiled: October 21, 2020Date of Patent: June 28, 2022Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Dingjiang Liu, Lin Luo, Long Xu
-
Publication number: 20220136073Abstract: Methods for characterizing DNA impurities in adeno-associated virus (AAV) samples or biopharmaceuticals are provided including the use of size exclusion chromatography and spectrophotometry. Methods and compositions are also provided to minimize leakage of packed DNA from AAV vector including the use of excipients, such as a sugar, an amino acid, a surfactant, or polyols.Type: ApplicationFiled: November 1, 2021Publication date: May 5, 2022Inventors: Bowen Jiang, Dingjiang Liu, Franco Tzul
-
Publication number: 20220065868Abstract: Methods and systems for identifying capsid viral proteins in a sample containing viral vectors are provided, including determining the ratio of the capsid viral proteins of adeno-associated virus. The methods and systems comprise denaturing the capsid viral proteins in the sample, labeling the denatured capsid viral proteins with a lysine-conjugation dye, generating a separation profile of the denatured/labeled capsid viral proteins using microchip capillary electrophoresis, quantifying levels of the capsid viral proteins based on the separation profile, determining a quantification ratio of the capsid viral proteins based on the separation profile, and normalizing the quantification ratio based on lysine contents of the capsid viral proteins.Type: ApplicationFiled: August 28, 2021Publication date: March 3, 2022Inventors: Bowen Jiang, Franco Tzul, Dingjiang Liu
-
Publication number: 20210268404Abstract: The present disclosure relates to, inter alia, a method of quantitating an amount of an antibody molecule from a mixture comprising two or more antibody molecules, comprising separating each of the two or more antibody molecules from the mixture by hydrophobic interaction chromatography high performance liquid chromatography (HIC-HPLC) and quantitating an amount of each antibody molecule, wherein the molecular weight of each antibody molecule is within 15 kDa of any other antibody molecule in the mixture and either each antibody molecule is different from another antibody molecule in the mixture by more than about 0.25 unit on the Kyte & Doolittle hydropathy scale or each of the antibody molecules when nm alone on HIC-HPLC elutes at distinct run time with little overlap from the other antibody molecules in the mixture, or both.Type: ApplicationFiled: May 17, 2021Publication date: September 2, 2021Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Dingjiang LIU, Lin LUO, Long XU
-
Publication number: 20210252146Abstract: The present disclosure provides stable pharmaceutical formulations comprising a human antibody that specifically binds to Ebola Virus (EBOV). In certain embodiments, the formulations contain, in addition to an anti-EBOV antibody, a buffer, an amino acid, a non-ionic surfactant, and a stabilizer. The pharmaceutical formulations of the present disclosure exhibit a substantial degree of antibody stability upon stress, for example, agitation during transport, and storage, for example, storage at temperatures greater than 40° C.Type: ApplicationFiled: January 22, 2021Publication date: August 19, 2021Inventors: Yuan Cao, Dingjiang Liu, Long Xu
-
Patent number: 11020686Abstract: The present disclosure relates to, inter alia, a method of quantitating an amount of an antibody molecule from a mixture comprising two or more antibody molecules, comprising separating each of the two or more antibody molecules from the mixture by hydrophobic interaction chromatography high performance liquid chromatography (HIC-HPLC) and quantitating an amount of each antibody molecule, wherein the molecular weight of each antibody molecule is within 15 kDa of any other antibody molecule in the mixture and either each antibody molecule is different from another antibody molecule in the mixture by more than about 0.25 unit on the Kyte & Doolittle hydropathy scale or each of the antibody molecules when nm alone on HIC-HPLC elutes at distinct run time with little overlap from the other antibody molecules in the mixture, or both.Type: GrantFiled: August 8, 2017Date of Patent: June 1, 2021Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Dingjiang Liu, Lin Luo, Long Xu
-
Publication number: 20210054050Abstract: The present invention provides methods and systems for formulation optimization of bispecific antibodies. The present application also provides methods and systems to select molecule candidates for constructing bispecific antibodies and formulation optimization thereof. Physico-chemical parameters of a bispecific antibody are characterized. The formulation optimization strategies are guided by the prediction of interaction parameters. Various formulation optimization strategies are provided based on these physico-chemical parameters.Type: ApplicationFiled: August 20, 2020Publication date: February 25, 2021Inventors: Chen Zhou, Wenhua Wang, Dingjiang Liu
-
Publication number: 20210031123Abstract: The present disclosure relates to, inter alia, a method of quantitating an amount of an antibody molecule from a mixture comprising two or more antibody molecules, comprising separating each of the two or more antibody molecules from the mixture by hydrophobic interaction chromatography high performance liquid chromatography (HIC-HPLC) and quantitating an amount of each antibody molecule, wherein the molecular weight of each antibody molecule is within 15 kDa of any other antibody molecule in the mixture and either each antibody molecule is different from another antibody molecule in the mixture by more than about 0.25 unit on the Kyte & Doolittle hydropathy scale or each of the antibody molecules when run alone on HIC-HPLC elutes at distinct run time with little overlap from the other antibody molecules in the mixture, or both.Type: ApplicationFiled: October 21, 2020Publication date: February 4, 2021Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Dingjiang LIU, Lin LUO, Long XU
-
Publication number: 20200399384Abstract: The present disclosure relates to AM-14 pharmaceutical formulations and therapeutic dosing regimens for the treatment of disease.Type: ApplicationFiled: September 8, 2020Publication date: December 24, 2020Inventors: Dingjiang Liu, Holly Zhuohong Huang, David Andrew Martin, Christopher Boyd Russell, David H. Salinger, Scott Walter Baumgartner, Christopher Endres